Business Wire

Philip Morris International Announces Appointment of Two Former U.S. FDA Officials, Highlighting the Company’s Continued Commitment to Smoke-Free Product Science and Regulation

Share

Philip Morris International Inc. (PMI) (NYSE: PM) announced today that it has appointed two former United States Food and Drug Administration (U.S. FDA) officials to key positions to accelerate its science-based transformation.

Dr. Badrul Chowdhury is appointed PMI’s Chief Life Sciences Officer, Smoke-Free Products, succeeding Jorge Insuasty, who will complete his move into the recently created position of President, Vectura Fertin Pharma. After a short transition period, Badrul will join PMI’s Senior Management Team in January 2023, reporting to Jacek Olczak, Chief Executive Officer.

“I am delighted to welcome Badrul to PMI and look forward to working closely with him as he leads our talented team of scientific experts,” said Jacek Olczak. “He is an accomplished scientist and regulatory strategist, with decades of leadership experience, both in industry and as a regulator within the U.S. FDA’s Pulmonary Division. His wealth of knowledge and experience will be critical to help achieve our ambition of a smoke-free future. I also extend my sincere thanks to Jorge Insuasty for his contributions to the function as he moves to oversee Vectura Fertin Pharma full-time.”

Dr. Chowdhury joins PMI from a U.S.-based biotech company developing inhalation products for rare respiratory diseases, where he was Chief Medical Officer. Prior to that, he was AstraZeneca’s Senior Vice President and Chief Physician-Scientist for Respiratory Inflammation and Autoimmunity Late-Stage Development in Biopharmaceuticals R&D. Before joining the pharmaceutical industry, Dr. Chowdhury served as Director, Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and Research (CDER) at the U.S. FDA for almost 21 years, from 1997 to 2018, providing scientific and regulatory oversight of therapies for lung, autoimmune, and inflammatory diseases. Dr. Chowdhury is a medical doctor and holds a PhD in immunology.

“Joining the PMI team is an exciting new adventure,” said Dr. Chowdhury. “The investment the company has already made in delivering high-quality science to support its transformation and smoke-free vision is unprecedented. I am thrilled to have the chance to help move the company forward faster and to truly seize the public health opportunity that well-regulated smoke-free products present. I look forward to working with the Senior Management Team and the entire Life Sciences function to accelerate progress.”

Dr. Matthew (“Matt”) Holman is appointed as PMI’s Vice President of U.S. Scientific Engagement and Regulatory Strategy, reporting to Deepak Mishra, President of PMI Americas.

“We are delighted that Matt will be joining PMI to further accelerate our journey toward a smoke-free future, particularly here in the United States,” said Deepak Mishra. “As we transform, we recognize the importance of bringing together diverse perspectives, including those of regulatory bodies and the scientific community. Matt’s solid scientific and stakeholder knowledge, combined with his passion for tobacco harm reduction, will be invaluable.”

Dr. Holman joins PMI from the U.S. FDA, where he served for more than 20 years, most recently as Director of the Office of Science at the Center for Tobacco Products (CTP). At CTP, Holman was instrumental in building the FDA’s marketing application review programs. He served as CTP’s chief scientist, playing a significant role in guiding policy decisions, developing rulemaking and guidance documents, and overseeing a robust regulatory science research program for tobacco products. Previously, Holman worked at the FDA’s CDER on over-the-counter drug products, including as Deputy Director of the Division of Nonprescription Regulation Development. He received his PhD in biochemistry from the University of Maryland at College Park.

“Having spent more than two decades working to improve public health as a regulator, I am delighted to join forces with PMI, a company that is firmly committed to the goal of accelerating the end of smoking,” said Dr. Holman. “PMI is leading the industry in a major transformation that can ultimately provide an unprecedented breakthrough for public health. I’m excited to make this move and join PMI on its smoke-free journey.”

The appointment of these seasoned scientific and regulatory experts complements the recent hiring of Keagan Lenihan, who joined PMI in May 2022 as Vice President of Government Affairs and Public Policy, and Head of its D.C. office. Lenihan spent two decades working in government, corporate, and public policy, including as Associate Commissioner for External Affairs and Strategic Initiatives and then Chief of Staff at the U.S. FDA.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate, and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of versions of PMI’s IQOS Platform 1 devices and consumables as Modified Risk Tobacco Products (MRTPs), finding that exposure modification orders for these products are appropriate to promote the public health. As of June 30, 2022, excluding Russia and Ukraine, PMI’s smoke-free products were available for sale in 70 markets, and PMI estimates that approximately 13.2 million adults around the world had already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs. For more information, please visit www.pmi.com and www.pmiscience.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

David Fraser
Philip Morris International
T. +41 (0)58 242 4500
E. david.fraser@pmi.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ONWARD Announces Participation at Upcoming Events in October29.9.2022 07:30:00 CEST | Press release

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced that management will participate in the following upcoming events in October: Investors’ Day Geneva October 5, 2022 Geneva, Switzerland Dave Marver, CEO, will give a company presentation. The 3rd Annual Reeve Summit October 13-14, 2022 Washington, DC USA Dave Marver will participate in a keynote session, The Power of Partnership to Speed Cures to Market, with Marco Baptista, Chief Scientific Officer, Christopher & Dana Reeve Foundation. Oppenheimer Healthcare Showcase October 18, 2022 Palo Alto, CA USA Lara Smith Weber, CFO, will give a company presentation and participate in 1:1 meetings. VFB Soirées (Flemish Federation of Investors) October 27, 2022 Virtual event at 19:30 CET Dave Marver, CEO, will give a company presentation. Information on upcoming conferences is available in the investor

Mavenir Launches 5G Small Cell for High-Capacity In-building Standalone Coverage29.9.2022 07:30:00 CEST | Press release

Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced the unveiling of its latest 5G small cell at the upcoming India Mobile Congress (IMC) event in Pragati Maidan, New Delhi. Mavenir’s 5G small cell (E511), is a globally applicable product, with the flexibility to support both distributed and centralized ORAN architectures. Building on an established install base of over 2 million small cell units deployed globally, the 5G small cell forms part of an expanding small cell portfolio, that leverages Mavenir’s end-to-end RAN solution including a common Management System and CU. This flexibility, coupled with zero touch provisioning - ease of deployment, cost-effective, high-capacity solution is ideal for a variety of deployment use cases, including Enterprises such as office, retail, warehousing, manufacturing, and public spaces. Puneet Sethi, Mavenir’s SVP and GM

The LYCRA Company Announces Collaboration With Qore ® to Use QIRA ® for Next Generation Bio-derived LYCRA ® Fiber at Scale29.9.2022 02:00:00 CEST | Press release

The LYCRA Company,a global leader in developing innovative fiber and technology solutions for the textile and apparel industry, today announced it has entered into an agreement with Qore® to enable the world’s first large-scale commercial production of bio-derived spandex using QIRA®, the next generation 1,4-butanediol (BDO), as one of its main ingredients. This will result in 70% of the LYCRA® fiber content being derived from annually renewable feedstock. This change could potentially reduce the carbon footprint of LYCRA® fiber by up to 44%* versus equivalent product made from fossil-based resources, while maintaining the same high-quality performance parameters of traditional LYCRA® fiber. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220928005020/en/ The LYCRA Company signs an agreement with Qore® LLC to enable large-scale production of bio-derived spandex. Pictured – Julien Born, CEO of The LYCRA Company (left), and Jon

Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation ™28.9.2022 22:30:00 CEST | Press release

Mainstay Medical Holdings plc today announced the publication of the three-year patient outcomes data from its pivotal ReActiv8-B clinical trial. The data, published in the journal of the International Neuromodulation Society, Neuromodulation,further establish the efficacy and safety of ReActiv8 Restorative Neurostimulation, including compelling long-term durability and improvement over time on key outcome measures in the treatment of intractable chronic low back pain. The three-year data show improvements over results from the patients’ one-year and two-year visits on virtually all key efficacy measures. Of note: Outcome measure 1-year result (N = 176) 2-year result (N = 156) 3-year result (N = 133) Patients reporting pain intensity (Visual Analog Scale (VAS) score) reduced by 50% or more from baseline 64% 71% 77% Patients reporting a greater than 20-point reduction in Oswestry Disability Index 57% 61% 63% Patients reporting VAS score < 2.5 52% 65% 67% Patients taking opioids at basel

New Study From Egon Zehnder and Kearney Debunks the Myth of a Workplace Generational Divide28.9.2022 16:00:00 CEST | Press release

Egon Zehnder, the world’s preeminent leadership advisory firm, in partnership with Kearney, a leading global management consulting firm, today released findings from a new survey with over 8,000 respondents from eight different countries dismissing the myth of a generation divide in the workplace and showing that despite what is often believed, Gen Z, Millennials, Gen X and Boomers are more alike than different when it comes to workplace matters. The survey, titled “Different Generations, Same Ideals: What Workers of All Ages Value in their Jobs,” analyzed the similarities and differences among generations and found that they share more commonalities, especially when it comes to personal well-being, work-life balance, and desired traits from leadership. The most notable difference between the generations is how each group defines and plans to achieve their career desires. Key Findings from the survey include: Personal well-being, stability, and work-life balance matter more than money

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom